Webinar Overview
Chimeric Antigen Receptor (CAR)-based therapies are rapidly developing in oncology and other fields. With notable improvements in efficacy, safety, and complexity comes an increased need to streamline the development process. The FDA has approved six CAR-T cell products for the treatment of hematological malignancies, and many more T cell therapies are in the pipeline for both liquid and solid tumors as well as other clinical indications.
Packaging of CAR plasmids into viral vectors and subsequent primary cell transduction for CAR-T cell generation can cost you valuable time and money as well as limit the number of constructs that can be assessed simultaneously. Alternative screening methods in the Jurkat cell line (“CAR-J") allow you to identify, design, and optimize binders for the target of interest as well as test their in vitro and in vivo performance, facilitating a successful entrance into the clinic.
In this webinar you will learn:
- How to screen multiple CAR constructs, test engagement and optimise scFv for earlier identification of optimal constructs
- How to test the efficacy and safety of your CAR cell product in vitro
- Which animal models can be used for preclinical testing of your CAR cell product
Webinar Presenters
Lauren Schewitz-Bowers, PhD
Group Leader, Advanced Modalities
Charles River
Sabrina de Munnik, PhD
Senior Scientist II, Advanced Modalities
Charles River
Eva Oswald, PhD
Associate Research Director
Charles River